Scholarlink

<p>The pharmacokinetics of tranexamic acid (TXA), used during cardiopulmonary bypass (CPB) surgery, in patients receiving maintenance hemodialysis remain unclear. This prospective study compared serum tranexamic acid (TXA) concentrations following bolus administration and subsequent intensive care unit (ICU) admission in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), including those receiving maintenance hemodialysis and those not on dialysis. Participants received two TXA boluses: 1000&#xa0;mg (500&#xa0;mg for patients receiving hemodialysis) at procedure initiation and another 1000&#xa0;mg (500&#xa0;mg for patients receiving hemodialysis) after CPB withdrawal. Blood samples were collected at 30, 60, and 120&#xa0;min, and after CPB weaning after the first dose; following the second dose; upon ICU admission; and at 4, 8, and 12&#xa0;h post-ICU admission to measure TXA concentrations. A renal function-based simulation model was developed to optimize TXA dosing. Among 82 patients (74 without dialysis and 8 receiving hemodialysis), serum TXA concentrations were similar between groups until ICU admission. Following CPB withdrawal, patients receiving hemodialysis exhibited higher TXA concentrations than non-dialysis patients, despite receiving only half the total dose. TXA concentrations remained significantly higher in hemodialysis patients after ICU admission. Bolus administration effectively maintained antifibrinolytic TXA levels (&gt; 10&#xa0;µg/mL). The renal function-based model guides optimal TXA dosing strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Changes in blood concentration of tranexamic acid in dialysis and non-dialysis patients undergoing cardiac surgery: a prospective observational cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月25日

查看全文
  • Takahiro Tamura,
  • Tatsuro Yokoyama,
  • Tsuyoshi Nakai,
  • Yasuhiro Miyagawa,
  • Kimitoshi Nishiwaki

摘要

The pharmacokinetics of tranexamic acid (TXA), used during cardiopulmonary bypass (CPB) surgery, in patients receiving maintenance hemodialysis remain unclear. This prospective study compared serum tranexamic acid (TXA) concentrations following bolus administration and subsequent intensive care unit (ICU) admission in patients undergoing cardiac surgery with cardiopulmonary bypass (CPB), including those receiving maintenance hemodialysis and those not on dialysis. Participants received two TXA boluses: 1000 mg (500 mg for patients receiving hemodialysis) at procedure initiation and another 1000 mg (500 mg for patients receiving hemodialysis) after CPB withdrawal. Blood samples were collected at 30, 60, and 120 min, and after CPB weaning after the first dose; following the second dose; upon ICU admission; and at 4, 8, and 12 h post-ICU admission to measure TXA concentrations. A renal function-based simulation model was developed to optimize TXA dosing. Among 82 patients (74 without dialysis and 8 receiving hemodialysis), serum TXA concentrations were similar between groups until ICU admission. Following CPB withdrawal, patients receiving hemodialysis exhibited higher TXA concentrations than non-dialysis patients, despite receiving only half the total dose. TXA concentrations remained significantly higher in hemodialysis patients after ICU admission. Bolus administration effectively maintained antifibrinolytic TXA levels (> 10 µg/mL). The renal function-based model guides optimal TXA dosing strategies.